Neurocrine Biosciences, Inc.
MX ˙ BMV ˙ US64125C1099
SecurityMX:NBIX / Neurocrine Biosciences, Inc.
InstitutionLegal & General Group Plc
Latest Disclosed Ownership380,589 shares
Latest Disclosed Value $ 50,138,796
Legal & General Group Plc reports 15.12% increase in ownership of NBIX / Neurocrine Biosciences, Inc.

On May 8, 2026 - Legal & General Group Plc filed a 13F-HR form disclosing ownership of 380,589 shares of Neurocrine Biosciences, Inc. (MX:NBIX) valued at $50,138,796 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 9, 2026 disclosing 330,606 shares of Neurocrine Biosciences, Inc.. This represents a change in shares of 15.12% during the quarter.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-08 2026-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 380,589 49,983 15.12 50,139 6.93 0.0116
2026-02-09 2025-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 330,606 -69,564 -17.38 46,890 -16.53 0.0104
2025-11-13 2025-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 400,170 744 0.19 56,176 11.90 0.0126
2025-08-12 2025-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 399,426 16,499 4.31 50,204 18.54 0.0125
2025-05-15 2025-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 382,927 37,237 10.77 42,352 -10.25 0.0115
2025-02-13 2024-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 345,690 -44,895 -11.49 47,187 4.85 0.0125
2025-02-28 2024-09-30 13F/A-2 NEUROCRINE BIOSCIENCES COM 64125C109 390,585 -11,914 -2.96 45,003 -18.78 0.0118
2024-11-14 2024-09-30 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 529,260 -44,902 60,981 0.0127
2024-11-14 2024-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 529,260 -44,902 60,981 0.0064
2025-05-29 2024-06-30 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 402,499 -117 -0.03 55,412 -0.21 0.0157
2024-08-14 2024-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 574,162 34,056 79,045 0.0177
2025-05-29 2024-03-31 13F/A-2 NEUROCRINE BIOSCIENCES COM 64125C109 402,616 -38,891 -8.81 55,529 -4.55 0.0160
2024-07-01 2024-03-31 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 540,106 -36,782 74,491 0.0174
2024-05-14 2024-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 540,106 -36,782 74,491 0.0090
2025-05-29 2023-12-31 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 441,507 -6,641 -1.48 58,173 15.38 0.0181
2024-02-15 2023-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 576,888 128,740 76,011 0.0195
2023-11-14 2023-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 448,148 -9,584 -2.09 50,417 16.80 0.0176
2023-08-14 2023-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 457,732 -36,186 -7.33 43,164 -13.66 0.0140
2023-05-15 2023-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 493,918 2,696 0.55 49,994 -14.79 0.0179
2023-02-14 2022-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 491,222 -5,816 -1.17 58,672 11.14 0.0225
2022-11-14 2022-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 497,038 -9,672 -1.91 52,791 6.88 0.0206
2022-08-22 2022-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 506,710 33,279 7.03 49,394 11.29 0.0175
2022-05-16 2022-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 473,431 26,254 5.87 44,384 16.53 0.0135
2022-02-14 2021-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 447,177 -2,944 -0.65 38,087 -11.78 0.0115
2021-11-15 2021-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 450,121 1,625 0.36 43,171 -1.09 0.0140
2021-08-12 2021-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 448,496 42,915 10.58 43,648 10.66 0.0146
2021-05-17 2021-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 405,581 66,890 19.75 39,443 21.50 0.0147
2021-02-12 2020-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 338,691 -29,488 -8.01 32,463 -8.31 0.0127
2020-11-13 2020-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 368,179 -9,306 -2.47 35,405 -23.18 0.0158
2020-08-14 2020-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 377,485 94,980 33.62 46,091 88.50 0.0223
2020-05-14 2020-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 282,505 21,196 8.11 24,451 -12.95 0.0143
2020-02-13 2019-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 261,309 209,011 399.65 28,088 536.05 0.0134
2019-08-14 2019-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 52,298 718 1.39 4,416 -2.82 0.0024
2019-05-15 2019-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 51,580 -8,987 -14.84 4,544 5.06 0.0026
2019-02-15 2018-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 60,567 -4,598 -7.06 4,325 -46.02 0.0034
2018-11-20 2018-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 65,165 25,365 63.73 8,012 104.91 0.0057
2018-08-10 2018-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 39,800 -5,011 -11.18 3,910 5.22 0.0030
2018-05-17 2018-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 44,811 -561 -1.24 3,716 5.57 0.0028
2018-02-13 2017-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 45,372 8,875 24.32 3,520 57.35 0.0025
2017-11-09 2017-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 36,497 4,638 14.56 2,237 52.70 0.0017
2017-08-03 2017-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 31,859 2,554 8.72 1,465 15.45 0.0012
2017-05-12 2017-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 29,305 19,955 213.42 1,269 250.55 0.0011
2017-02-13 2016-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 9,350 1,136 13.83 362 -12.77 0.0003
2016-10-12 2016-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 8,214 1,215 17.36 415 30.50 0.0004
2016-08-16 2016-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 6,999 -12,289 -63.71 318 -58.10 0.0003
2016-05-16 2016-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 19,288 1,862 10.69 759 -22.55 0.0008
2016-02-16 2015-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 17,426 958 5.82 980 56.05 0.0011
2015-11-13 2015-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 16,468 688 4.36 628 -16.27 0.0008
2015-07-31 2015-06-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 15,780 1,926 13.90 750 32.28 0.0009
2015-05-14 2015-03-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 13,854 2,418 21.14 567 119.77 0.0007
2015-02-20 2014-12-31 13F/A-1 NEUROCRINE BIOSCIENCES COM 64125C109 11,436 0 0.00 258 44.94 0.0003
2015-02-17 2014-12-31 13F NEUROCRINE BIOSCIENCES COM 64125C109 11,436 0 258 0.0003
2014-11-14 2014-09-30 13F NEUROCRINE BIOSCIENCES COM 64125C109 11,436 11,436 178 0.0002
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.